Philip P. Connell
Title | Professor |
---|
Institution | University of Chicago |
---|
Department | Radiation and Cellular Oncology |
---|
Address | Chicago IL 60637
|
---|
vCard | Download vCard |
---|
|
|
|
Overview Philip Connell, MD, is an expert in radiotherapy with a particular focus on sarcomas, thoracic cancers, and pediatric malignancies. This year he was again recognized by Newsweek as one of “America's Top Doctors” and by Chicago Magazine as a “Top Doctor” in the Chicagoland region. In addition to his clinical responsibilities, Dr. Connell is an active cancer researcher. He received laboratory training in cancer biology through a National Cancer Institute fellowship. His oncology research program is working to identify molecular markers of treatment resistance and to develop new anti-cancer agents that can overcome these molecular hurdles. His newest ongoing projects involve several novel, high-throughput assays designed to identify potential drugs that modify DNA repair. With these systems, researchers have the potential to discover new chemical compounds with wide-ranging impacts--from improving present oncology therapies to blocking the mutagenic effects of chemotherapy and radiotherapy.
Dr. Connell has received several awards including the American Society of Clinical Oncology Merit Award, American Brachytherapy Society Research Award, Roentgen Society Research Award, Samuel Hellman Teacher of the Year Award, and American Society for Therapeutic Radiology and Oncology Junior Faculty Fellowship Award. He has authored numerous medical reports and textbook chapters, and he serves as a reviewer for numerous medical journals.
Biography Tufts University, Medford, MA | BS | 1991 | Chemical engineering | New York Medical College, Valhalla, NY | MD | 1995 | Medicine | St. Vincent’s Hospital, New York, NY | Internship | 1996 | Internal medicine | University of Chicago, Chicago, Il | Residency | 2000 | Radiation Oncology | University of Chicago, Chicago, Il | NIH Research Fellow | 2001 | Cancer research |
2015 - 2021 | Recognized as one of “America's Top Doctors” , Newsweek | 2015 - 2021 | Recognized as a “Top Doctor”, Chicago Magazine | 2016 | Best basic/translational science , Annual Meeting of the American Society for Radiation Oncology | 2004 - 2005 | American Society for Therapeutic Radiology and Oncology Junior Faculty , U Chicago | 2003 | Samuel Hellman Teaching Award, U Chicago | 2001 | Young Investigator Grant Award, Cancer Research Foundation | 1999 | Roentgen Society Research Award, Roentgen Society | 1999 | American Brachytherapy Society Research Award, American Brachytherapy Society | 1997 | American Society of Clinical Oncology Merit Award, American Society of Clinical Oncology |
Research R21CA124557 (CONNELL, PHILIP PAUL)Jul 1, 2007 - Jun 30, 2010 NIH Inhibition of Recombination DNA Repair in Pancreatic Cancer Cells Role: Principal Investigator |
| R01CA142642 (CONNELL, PHILIP P)Dec 1, 2009 - Jun 30, 2020 NIH RAD51 Inhibitors for Chemotherapy and Radiation Therapy Role: Principal Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Budke B, Zhong A, Sullivan K, Park C, Gittin DI, Kountz TS, Connell PP. Noncanonical NF-?B factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy. Nucleic Acids Res. 2022 06 24; 50(11):6251-6263. PMID: 35689636.
-
Xu J, Zhao L, Peng S, Chu H, Liang R, Tian M, Connell PP, Li G, Chen C, Wang HW. Mechanisms of distinctive mismatch tolerance between Rad51 and Dmc1 in homologous recombination. Nucleic Acids Res. 2021 12 16; 49(22):13135-13149. PMID: 34871438.
-
Zuo K, Yuan X, Liang X, Sun X, Liu S, Connell PP, Li X, Yang W. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Jan; 191(2):335-344. PMID: 34797456.
-
Pointer KB, Budke B, Connell PP. Targeting Non-Canonical NF?B2 to Determine the Effects on Radiation Sensitization. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e229-e230. PMID: 34700966.
-
Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059. PMID: 34625620.
-
Rosenberg DM, Onderdonk B, Majeed NK, Guzman G, Farid Y, Connell PP, Son CH. Radiation-Induced Sarcoma After Heterotopic Ossification Prophylaxis: A Case Report. JBJS Case Connect. 2019 Dec; 9(4):e0146. PMID: 31815809.
-
Tatebe K, Chmura SJ, Connell PP. Elevated Radiation Therapy Toxicity in the Setting of Germline PTEN Mutation. Pract Radiat Oncol. 2019 Nov; 9(6):492-495. PMID: 31185301.
-
Ni L, Koshy M, Connell P, Pitroda S, Golden DW, Al-Hallaq H, Hubert G, Kauffman G, McCall A, Malik R. Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation. J Thorac Dis. 2019 Jun; 11(6):2229-2239. PMID: 31372260.
-
Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP. Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51. ChemMedChem. 2019 05 17; 14(10):1031-1040. PMID: 30957434.
-
Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516. PMID: 30674566.
-
Chmura SJ, Connell PP, Weichselbaum RR. Retuning the Radio in Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):325-326. PMID: 29126281.
-
Akthar AS, Koshy M, Ferguson MK, Murgu S, Hogarth DK, Golden DW, Connell PP, Davies EM, Kowalski E, Malik R. Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy. Clin Lung Cancer. 2018 03; 19(2):e227-e233. PMID: 28939097.
-
Ni L, Koshy M, Connell PP, Hubert G, Vokes EE, Patel JD, Hoffman P, Al-Hallaq HA, Malik R. Impact of Cardiac Dose on Cardiac Events and Survival in Unresectable Lung Cancer Patients. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):247. PMID: 28587036.
-
Pitroda SP, Bao R, Andrade J, Weichselbaum RR, Connell PP. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500. PMID: 28341751.
-
Budke B, Lv W, Kozikowski AP, Connell PP. Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy? ChemMedChem. 2016 11 21; 11(22):2468-2473. PMID: 27781374.
-
Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. J Med Chem. 2016 05 26; 59(10):4511-25. PMID: 27049177.
-
Spiotto MT, Connell PP. Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers. Oral Maxillofac Surg Clin North Am. 2016 Feb; 28(1):115-26. PMID: 26614704.
-
Thierry S, Benleulmi MS, Sinzelle L, Thierry E, Calmels C, Chaignepain S, Waffo-Teguo P, Merillon JM, Budke B, Pasquet JM, Litvak S, Ciuffi A, Sung P, Connell P, Hauber I, Hauber J, Andreola ML, Delelis O, Parissi V. Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration. Chem Biol. 2015 Jun 18; 22(6):712-23. PMID: 26051216.
-
Mason JM, Dusad K, Wright WD, Grubb J, Budke B, Heyer WD, Connell PP, Weichselbaum RR, Bishop DK. RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. Nucleic Acids Res. 2015 Mar 31; 43(6):3180-96. PMID: 25765654.
-
Mason JM, Logan HL, Budke B, Wu M, Pawlowski M, Weichselbaum RR, Kozikowski AP, Bishop DK, Connell PP. The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res. 2014 Jul 01; 74(13):3546-55. PMID: 24753542.
-
Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42. PMID: 24670686.
-
Connell PP, Weichselbaum RR. Small molecule derived from a natural product that mitigates radiation injury. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18355-6. PMID: 24187150.
-
Budke B, Chan YL, Bishop DK, Connell PP. Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. Nucleic Acids Res. 2013 Jul; 41(13):e130. PMID: 23666628.
-
Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013 Feb 20; 5(173):173sr2. PMID: 23427246.
-
Spraker MB, Bair E, Bair R, Connell PP, Mahmood U, Koshy M. An analysis of patient characteristics and clinical outcomes in primary pulmonary sarcoma. J Thorac Oncol. 2013 Feb; 8(2):147-51. PMID: 23263688.
-
Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, Connell PP. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10; 56(1):254-63. PMID: 23231413.
-
Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, Connell PP. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012 Aug; 40(15):7347-57. PMID: 22573178.
-
Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81. PMID: 22198429.
-
Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70. PMID: 22020702.
-
Cosnefroy O, Tocco A, Lesbats P, Thierry S, Calmels C, Wiktorowicz T, Reigadas S, Kwon Y, De Cian A, Desfarges S, Bonot P, San Filippo J, Litvak S, Cam EL, Rethwilm A, Fleury H, Connell PP, Sung P, Delelis O, Andréola ML, Parissi V. Stimulation of the human RAD51 nucleofilament restricts HIV-1 integration in vitro and in infected cells. J Virol. 2012 Jan; 86(1):513-26. PMID: 22013044.
-
Connell PP, Weichselbaum RR. A downside to apoptosis in cancer therapy? Nat Med. 2011 Jul 07; 17(7):780-2. PMID: 21738153.
-
Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50. PMID: 21676484.
-
MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, Connell PP. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1147-53. PMID: 19577863.
-
Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009 Jan 15; 69(2):383-92. PMID: 19147546.
-
Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL, Weichselbaum RR, Bishop DK, Connell PP. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A. 2008 Oct 14; 105(41):15848-53. PMID: 18840682.
-
Martin RW, Connell PP, Bishop DK. The Yin and Yang of treating BRCA-deficient tumors. Cell. 2008 Mar 21; 132(6):919-20. PMID: 18358803.
-
Knab B, Connell PP. Radiotherapy for pediatric brain tumors: when and how. Expert Rev Anticancer Ther. 2007 Dec; 7(12 Suppl):S69-77. PMID: 18076312.
-
Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63. PMID: 17551302.
-
Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22. PMID: 17255273.
-
Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9. PMID: 16596227.
-
Connell PP, Fulcher TP, Chacko E, O' Connor MJ, Moriarty P. Long term follow up of nasolacrimal intubation in adults. Br J Ophthalmol. 2006 Apr; 90(4):435-6. PMID: 16547322.
-
Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Obasaju C, Haraf DJ, Salgia R, Vokes EE. A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):7062. PMID: 27944519.
-
Connell P, McKevitt C, Low N. Investigating ethnic differences in sexual health: focus groups with young people. Sex Transm Infect. 2004 Aug; 80(4):300-5. PMID: 15295130.
-
Connell PP, Kron SJ, Weichselbaum RR. Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst). 2004 Aug-Sep; 3(8-9):1245-51. PMID: 15279813.
-
Connell PP, Siddiqui N, Hoffman S, Kuang A, Khatipov EA, Weichselbaum RR, Bishop DK. A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin. Cancer Res. 2004 May 01; 64(9):3002-5. PMID: 15126333.
-
Connell PP, Weichselbaum RR. Gene therapy: the challenges of translating laboratory research into clinical practice. J Clin Oncol. 2003 Jun 15; 21(12):2230-1. PMID: 12805319.
-
Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1154-60. PMID: 11483324.
-
Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1145-53. PMID: 11483323.
-
Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol. 2001 Aug; 82(2):338-43. PMID: 11531290.
-
Connell PP, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani AB, Weichselbaum RR, Vijayakumar S. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61. PMID: 11134195.
-
Jani AB, Connell PP, Vesich VJ, O'Brien KM, Chen LM. Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus. Am J Clin Oncol. 2000 Dec; 23(6):554-8. PMID: 11202794.
-
Mundt AJ, Waggoner S, Yamada D, Rotmensch J, Connell PP. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol. 2000 Oct; 79(1):79-85. PMID: 11006036.
-
Tran BN, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol. 2000 Oct; 23(5):476-80. PMID: 11039507.
-
Castro IM, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Synchronous ovarian and endometrial malignancies. Am J Clin Oncol. 2000 Oct; 23(5):521-5. PMID: 11039516.
-
Mundt AJ, Connell PP. Do conventional pathologic features lose their prognostic significance following postoperative radiation therapy in pathologic stage I-II endometrial adenocarcinoma? Int J Cancer. 2000 Aug 20; 90(4):224-30. PMID: 10993962.
-
Rotmensch J, Connell PP, Yamada D, Waggoner SE, Mundt AJ. One versus two intracavitary brachytherapy applications in early-stage cervical cancer patients undergoing definitive radiation therapy. Gynecol Oncol. 2000 Jul; 78(1):32-8. PMID: 10873406.
-
Wollschlaeger K, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Acute problems during low-dose-rate intracavitary brachytherapy for cervical carcinoma. Gynecol Oncol. 2000 Jan; 76(1):67-72. PMID: 10620444.
-
Connell PP, Ignacio L, McBride RB, Weichselbaum RR, Vijayakumar S. Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology. 1999 Nov; 54(5):875-9. PMID: 10565750.
-
Connell PP, Rotmensch J, Waggoner SE, Mundt AJ. Race and clinical outcome in endometrial carcinoma. Obstet Gynecol. 1999 Nov; 94(5 Pt 1):713-20. PMID: 10546716.
-
Calvin DP, Connell PP, Rotmensch J, Waggoner S, Mundt AJ. Surgery and postoperative radiation therapy in stage II endometrial carcinoma. Am J Clin Oncol. 1999 Aug; 22(4):338-43. PMID: 10440186.
-
Connell PP, Rotmensch J, Waggoner S, Mundt AJ. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol. 1999 Jul; 74(1):74-9. PMID: 10385554.
-
Weiss MF, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. External pelvic radiation therapy in stage IC endometrial carcinoma. Obstet Gynecol. 1999 Apr; 93(4):599-602. PMID: 10214841.
-
Mundt AJ, Connell PP, Mansur DB. What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy? Radiat Oncol Investig. 1999; 7(6):353-9. PMID: 10644058.
-
Mundt AJ, Connell PP, Campbell T, Hwang JH, Rotmensch J, Waggoner S. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol. 1998 Nov; 71(2):151-8. PMID: 9826453.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1998 | 1 | 1999 | 6 | 2000 | 7 | 2001 | 4 | 2003 | 1 | 2004 | 3 | 2005 | 1 | 2006 | 2 | 2007 | 3 | 2008 | 2 | 2009 | 2 | 2011 | 4 | 2012 | 3 | 2013 | 4 | 2014 | 2 | 2015 | 2 | 2016 | 3 | 2017 | 3 | 2018 | 1 | 2019 | 5 | 2021 | 4 | 2022 | 1 |
To return to the timeline, click here.
|
Connell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|